Last reviewed · How we verify

PADAGIS US — Portfolio Competitive Intelligence Brief

PADAGIS US pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Midamor AMILORIDE marketed Potassium-sparing Diuretic Amiloride-sensitive sodium channel, ENaC Immunology 1981-01-01
Verdeso DESONIDE marketed Corticosteroid [EPC] Glucocorticoid receptor Oncology 1972-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Aqua Pharms · 1 shared drug class
  3. Astellas Pharma · 1 shared drug class
  4. AstraZeneca K.K. · 1 shared drug class
  5. Eurofarma · 1 shared drug class
  6. Generic (originally Merck) · 1 shared drug class
  7. Generic (originally Merck/Upjohn) · 1 shared drug class
  8. Generic (originally Schering) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PADAGIS US:

Cite this brief

Drug Landscape (2026). PADAGIS US — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/padagis-us. Accessed 2026-05-17.

Related